Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany.
Hans-Peter TonyEugen FeistPeer Malte AriesSilke ZinkeKlaus KrügerJonas AhlersInka AlbrechtChristian BarrionuevoStefanie KalusHarald BurkhardtPublished in: Rheumatology advances in practice (2022)
Paul-Ehrlich-Institut-Federal Institute for Vaccine and Biomedics, SARILL08661.